Use of Machine Learning for Dosage Individualization of Vancomycin in Neonates.

Infant, Newborn Humans Vancomycin / pharmacokinetics Bayes Theorem Area Under Curve Drug Monitoring / methods Anti-Bacterial Agents / pharmacokinetics Retrospective Studies

Journal

Clinical pharmacokinetics
ISSN: 1179-1926
Titre abrégé: Clin Pharmacokinet
Pays: Switzerland
ID NLM: 7606849

Informations de publication

Date de publication:
08 2023
Historique:
accepted: 08 05 2023
medline: 31 7 2023
pubmed: 10 6 2023
entrez: 10 6 2023
Statut: ppublish

Résumé

High variability in vancomycin exposure in neonates requires advanced individualized dosing regimens. Achieving steady-state trough concentration (C C Before starting treatment, C C

Sections du résumé

BACKGROUND AND OBJECTIVE
High variability in vancomycin exposure in neonates requires advanced individualized dosing regimens. Achieving steady-state trough concentration (C
METHODS
C
RESULTS
Before starting treatment, C
CONCLUSION
C

Identifiants

DOI: 10.1007/s40262-023-01265-z PMID: 37300630
pubmed: 37300630
doi: 10.1007/s40262-023-01265-z
pii: 10.1007/s40262-023-01265-z
doi:

Substances chimiques

Vancomycin 6Q205EH1VU
Anti-Bacterial Agents 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

1105-1116

Informations de copyright

© 2023. The Author(s), under exclusive licence to Springer Nature Switzerland AG.

Références

Levine DP. Vancomycin: a history. Clin Infect Dis. 2006;42:S5–12.
doi: 10.1086/491709 pubmed: 16323120
Rybak MJ. The pharmacokinetic and pharmacodynamic properties of vancomycin. Clin Infect Dis. 2006;42(Suppl 1):S35–9. https://doi.org/10.1086/491712 .
doi: 10.1086/491712 pubmed: 16323118
Rybak M, et al. Therapeutic monitoring of vancomycin in adult patients: a consensus review of the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, and the Society of Infectious Diseases Pharmacists. Am J Health Syst Pharm. 2009;66:82–98. https://doi.org/10.2146/ajhp080434 .
doi: 10.2146/ajhp080434 pubmed: 19106348
Pham JT. Challenges of vancomycin dosing and therapeutic monitoring in neonates. J Pediatr Pharmacol Ther. 2020;25:476–84.
pubmed: 32839651 pmcid: 7439954
Wicha SG, et al. From therapeutic drug monitoring to model-informed precision dosing for antibiotics. Clin Pharmacol Ther. 2021;109(4):928–41.
doi: 10.1002/cpt.2202 pubmed: 33565627
Allegaert K, Flint R, Smits A. Pharmacokinetic modelling and Bayesian estimation-assisted decision tools to optimize vancomycin dosage in neonates: only one piece of the puzzle. Expert Opin Drug Metab Toxicol. 2019;15:735–49. https://doi.org/10.1080/17425255.2019.1655540 .
doi: 10.1080/17425255.2019.1655540 pubmed: 31402708
Roberts JA, et al. Individualised antibiotic dosing for patients who are critically ill: challenges and potential solutions. Lancet Infect Dis. 2014;14:498–509. https://doi.org/10.1016/S1473-3099(14)70036-2 .
doi: 10.1016/S1473-3099(14)70036-2 pubmed: 24768475 pmcid: 4181663
McComb M, Bies R, Ramanathan M. Machine learning in pharmacometrics: opportunities and challenges. Br J Clin Pharmacol. 2021. https://doi.org/10.1111/bcp.14801 .
doi: 10.1111/bcp.14801 pubmed: 33634893
Jacqz-Aigrain E, et al. Population pharmacokinetic meta-analysis of individual data to design the first randomized efficacy trial of vancomycin in neonates and young infants. J Antimicrob Chemother. 2019;74:2128–38. https://doi.org/10.1093/jac/dkz158 .
doi: 10.1093/jac/dkz158 pubmed: 31049551
An SH, Lee EM, Kim JY, Gwak HS. Vancomycin pharmacokinetics in critically ill neonates receiving extracorporeal membrane oxygenation. Eur J Hosp Pharm. 2020;27:E25–9. https://doi.org/10.1136/ejhpharm-2018-001720 .
doi: 10.1136/ejhpharm-2018-001720 pubmed: 32296501
Thomas CA, Picone A, Menon S, Willis BC. Empirical vancomycin dosing in pediatric patients with congenital heart disease and the impact of cardiopulmonary bypass on trough concentrations. Pharmacotherapy. 2018;37:1341–6.
doi: 10.1002/phar.2019
Stone SB, Benner K, Utley A, MacLennan P, Coghill CH 3rd. Achieving vancomycin troughs within goal range in low birth weight neonates. J Pediatr Pharmacol Ther. 2021;26:56–61. https://doi.org/10.5863/1551-6776-26.1.56 .
doi: 10.5863/1551-6776-26.1.56 pubmed: 33424501 pmcid: 7792141
Friedman JH. Greedy function approximation: a gradient boosting machine. Ann Stat. 2001;29:1189–232. https://doi.org/10.1214/aos/1013203451 .
doi: 10.1214/aos/1013203451
Dorogush AV, Ershov V, Gulin A. CatBoost: gradient boosting with categorical features support. 2018. https://arxiv.org/pdf/1810.11363.pdf . Accessed 3 Jun 2023.
Chen T, Tong H, Benesty M. xgboost: extreme gradient boosting. 2017. https://cran.microsoft.com/snapshot/2017-12-11/web/packages/xgboost/vignettes/xgboost.pdf . Accessed 3 Jun 2023.
Sheridan RP, Liaw A, Tudor M. Light gradient boosting machine as a regression method for quantitative structure–activity relationships. 2021. https://arxiv.org/pdf/2105.08626.pdf . Accessed 3 Jun 2023.
Hastie T, et al. The elements of statistical learning. Switzerland: Springer; 2009.
doi: 10.1007/978-0-387-84858-7
Basak D, Srimanta P, Patranbis DC. Support vector regression. Neural Inf Process Lett Rev. 2007;11:203–24.
Arik SO, Pfister T. TabNet: attentive interpretable tabular learning. 2019. https://arxiv.org/pdf/1908.07442.pdf . Accessed 3 Jun 2023.
Indyk, P. Approximate Nearest Neighbor: Towards Removing the Curse of Dimensionality. 1998. https://arxiv.org/pdf/1908.07442.pdf . Accessed 3 Jun 2023.
Ogami C, et al. An artificial neural network-pharmacokinetic model and its interpretation using Shapley additive explanations. CPT Pharmacometr Syst Pharmacol. 2021;10:760–8. https://doi.org/10.1002/psp4.12643 .
doi: 10.1002/psp4.12643
Wan M, Walker S, Elaine M, Marion E, Lesley P, Leis JA. The impact of vancomycin trough concentrations on outcomes in non-deep seated infections: a retrospective cohort study. BMC Pharmacol Toxicol. 2018;19:47.
doi: 10.1186/s40360-018-0236-z pubmed: 30064515 pmcid: 6069851
Kim J, et al. Determination of vancomycin pharmacokinetics in neonates to develop practical initial dosing recommendations. Antimicrob Agents Chemother. 2014;58:2830–40. https://doi.org/10.1128/AAC.01718-13 .
doi: 10.1128/AAC.01718-13 pubmed: 24614381 pmcid: 3993213
Tseng S-H, et al. Evaluating the relationship between vancomycin trough concentration and 24-hour area under the concentration–time curve in neonates. Antimicrob Agents Chemother. 2018. https://doi.org/10.1128/AAC.01647-17 .
doi: 10.1128/AAC.01647-17 pubmed: 29358290 pmcid: 5914004
Yao BF, et al. Predictive performance of pharmacokinetic model-based virtual trials of vancomycin in neonates: mathematics matches clinical observation. Clin Pharmacokinet. 2022;61:1027–38. https://doi.org/10.1007/s40262-022-01128-z .
doi: 10.1007/s40262-022-01128-z pubmed: 35513741
Hughes JH, Tong DMH, Faldasz JD, Frymoyer A, Keizer RJ. Evaluation of neonatal and paediatric vancomycin pharmacokinetic models and the impact of maturation and serum creatinine covariates in a large multicentre data set. Clin Pharmacokinet. 2022. https://doi.org/10.1007/s40262-022-01185-4 .
doi: 10.1007/s40262-022-01185-4 pubmed: 36404388 pmcid: 9898357
Sharland M. Manual of childhood infections: The Blue Book. Oxford: Oxford University Press; 2011.
doi: 10.1093/med/9780199573585.001.0001
Vancomycin hydrochloride for injection label from FDA. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/210274s000lbl.pdf .
Custer JW. The Harriet lane handbook. USA: Johns Hopkins Hospital; 2020.
Ponthier L, et al. Optimization of vancomycin initial dose in term and preterm neonates by machine learning. Pharm Res. 2022;39:2497–506. https://doi.org/10.1007/s11095-022-03351-6 .
doi: 10.1007/s11095-022-03351-6 pubmed: 35918452
Bououda M, et al. A machine learning approach to predict interdose vancomycin exposure. Pharm Res. 2022;39:721–31. https://doi.org/10.1007/s11095-022-03252-8 .
doi: 10.1007/s11095-022-03252-8 pubmed: 35411504
Huang X, et al. An ensemble model for prediction of vancomycin trough concentrations in pediatric patients. Drug Des Devel Ther. 2021;15:1549–59. https://doi.org/10.2147/DDDT.S299037 .
doi: 10.2147/DDDT.S299037 pubmed: 33883878 pmcid: 8053786
Nigo M, et al. PK-RNN-V E: a deep learning model approach to vancomycin therapeutic drug monitoring using electronic health record data. J Biomed Inf. 2022;133: 104166. https://doi.org/10.1016/j.jbi.2022.104166 .
doi: 10.1016/j.jbi.2022.104166
Elyasi S, Khalili H, Dashti-Khavidaki S, Mohammadpour A. Vancomycin-induced nephrotoxicity: mechanism, incidence, risk factors and special populations. A literature review. Eur J Clin Pharmacol. 2012;68:1243–55. https://doi.org/10.1007/s00228-012-1259-9 .
doi: 10.1007/s00228-012-1259-9 pubmed: 22411630
Al-Jebawi Y, Karalic K, Shekhawat P, Mhanna MJ. The concomitant use of vancomycin and piperacillin-tazobactam is associated with acute kidney injury (AKI) in extremely low birth weight infants (ELBW). J Neonat Perinat Med. 2022;15(2):303–9.
doi: 10.3233/NPM-210866
Zhao W, et al. Population pharmacokinetics and dosing optimization of vancomycin in children with malignant hematological disease. Antimicrob Agents Chemother. 2014;58:3191–9. https://doi.org/10.1128/AAC.02564-13 .
doi: 10.1128/AAC.02564-13 pubmed: 24663023 pmcid: 4068451

Auteurs

Bo-Hao Tang (BH)

Department of Clinical Pharmacy, Key Laboratory of Chemical Biology (Ministry of Education), School of Pharmaceutical Sciences, Cheeloo College of Medicine, Shandong University, Jinan, China.

Jin-Yuan Zhang (JY)

Beijing Medicinovo Technology Co. Ltd., Beijing, China.

Karel Allegaert (K)

Department of Development and Regeneration, KU Leuven, Leuven, Belgium.
Department of Pharmaceutical and Pharmacological Sciences, KU Leuven, Leuven, Belgium.
Department of Hospital Pharmacy, Erasmus MC, Rotterdam, the Netherlands.

Guo-Xiang Hao (GX)

Department of Clinical Pharmacy, Key Laboratory of Chemical Biology (Ministry of Education), School of Pharmaceutical Sciences, Cheeloo College of Medicine, Shandong University, Jinan, China.

Bu-Fan Yao (BF)

Department of Clinical Pharmacy, Key Laboratory of Chemical Biology (Ministry of Education), School of Pharmaceutical Sciences, Cheeloo College of Medicine, Shandong University, Jinan, China.

Stephanie Leroux (S)

Department of Pediatrics, CHU de Rennes, Rennes, France.

Alison H Thomson (AH)

Strathclyde Institute of Pharmacy and Biomedical Sciences, University of Strathclyde, Glasgow, UK.

Ze Yu (Z)

Beijing Medicinovo Technology Co. Ltd., Beijing, China.

Fei Gao (F)

Beijing Medicinovo Technology Co. Ltd., Beijing, China.

Yi Zheng (Y)

Department of Clinical Pharmacy, Key Laboratory of Chemical Biology (Ministry of Education), School of Pharmaceutical Sciences, Cheeloo College of Medicine, Shandong University, Jinan, China.

Yue Zhou (Y)

Department of Clinical Pharmacy, Key Laboratory of Chemical Biology (Ministry of Education), School of Pharmaceutical Sciences, Cheeloo College of Medicine, Shandong University, Jinan, China.

Edmund V Capparelli (EV)

Pediatric Pharmacology and Drug Discovery, University of California, San Diego, CA, USA.

Valerie Biran (V)

Neonatal Intensive Care Unit, Hospital Robert Debre, Paris, France.

Nicolas Simon (N)

Service de Pharmacologie Clinique, CAP-TV, Aix Marseille Univ, APHM, INSERM, IRD, SESSTIM, Hop Sainte Marguerite, Marseille, France.

Bernd Meibohm (B)

Department of Pharmaceutical Sciences, University of Tennessee Health Science Center, Memphis, TN, USA.

Yoke-Lin Lo (YL)

Department of Pharmacy, Faculty of Medicine, University of Malaya, Kuala Lumpur, Malaysia.
School of Pharmacy, International Medical University, Kuala Lumpur, Malaysia.

Remedios Marques (R)

Department of Pharmacy Services, La Fe Hospital, Valencia, Spain.

Jose-Esteban Peris (JE)

Department of Pharmacy and Pharmaceutical Technology, University of Valencia, Valencia, Spain.

Irja Lutsar (I)

Institute of Medical Microbiology, University of Tartu, Tartu, Estonia.

Jumpei Saito (J)

Department of Pharmacy, National Children's Hospital National Center for Child Health and Development, Tokyo, Japan.

Evelyne Jacqz-Aigrain (E)

Department of Pediatric Pharmacology and Pharmacogenetics, Hospital Robert Debre, APHP, Paris, France.
Clinical Investigation Center CIC1426, Hôpital Robert Debré, Paris, France.
University Paris Diderot, Sorbonne Paris Cite, Paris, France.

John van den Anker (J)

Division of Clinical Pharmacology, Children's National Hospital, Washington, DC, USA.
Department of Pediatrics, Pharmacology and Physiology, The George Washington University School of Medicine and Health Sciences, Washington, DC, USA.
Department of Genomics and Precision Medicine, The George Washington University School of Medicine and Health Sciences, Washington, DC, USA.
Department of Pediatric Pharmacology and Pharmacometrics, University of Basel Children's Hospital, Basel, Switzerland.

Yue-E Wu (YE)

Department of Clinical Pharmacy, Key Laboratory of Chemical Biology (Ministry of Education), School of Pharmaceutical Sciences, Cheeloo College of Medicine, Shandong University, Jinan, China.

Wei Zhao (W)

Department of Clinical Pharmacy, Key Laboratory of Chemical Biology (Ministry of Education), School of Pharmaceutical Sciences, Cheeloo College of Medicine, Shandong University, Jinan, China. zhao4wei2@hotmail.com.
NMPA Key Laboratory for Clinical Research and Evaluation of Innovative Drug, Qilu Hospital of Shandong University, Shandong University, Jinan, China. zhao4wei2@hotmail.com.
ORCID: 0000-0002-1830-338X

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Personnes › Tranches d'âge › Nourrisson › Nouveau-né › Use of Machine Learning for Dosage...
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › Use of Machine Learning for Dosage...
questionsmedicales.fr › Acides aminés, peptides et protéines › Peptides › Glycopeptides › Vancomycine › Use of Machine Learning for Dosage...
questionsmedicales.fr › Environnement et santé publique › Santé publique › Méthodes épidémiologiques › Statistiques comme sujet › Probabilité › Théorème de Bayes › Use of Machine Learning for Dosage...
questionsmedicales.fr › Environnement et santé publique › Santé publique › Méthodes épidémiologiques › Statistiques comme sujet › Aire sous la courbe › Use of Machine Learning for Dosage...
questionsmedicales.fr › Diagnostic › Techniques et procédures diagnostiques › Monitorage physiologique › Surveillance des médicaments › Use of Machine Learning for Dosage...
questionsmedicales.fr › Actions chimiques et utilisations › Actions pharmacologiques › Utilisations thérapeutiques › Anti-infectieux › Antibactériens › Use of Machine Learning for Dosage...
questionsmedicales.fr › Environnement et santé publique › Santé publique › Méthodes épidémiologiques › Caractéristiques des études épidémiologiques › Études épidémiologiques › Études de cohortes › Études rétrospectives › Use of Machine Learning for Dosage...